Why the study?
Does propafenone alter electrophysiological properties and prevent tachycardia recurrences in children with recurrent paroxysmal supraventricular tachycardia?
Does propafenone alter electrophysiological properties and prevent tachycardia recurrences in children with recurrent paroxysmal supraventricular tachycardia?
Propafenone is highly effective in terminating and preventing recurrences of paroxysmal supraventricular tachycardia in pediatric patients, with short-term EP testing predicting long-term oral efficacy.
Answers are grounded in this paper and cite their sources.
Propafenone was associated with high termination and prevention rates in pediatric PSVT; hypothesis-generating and should not yet change practice pending RCTs.
Twenty-four patients aged 10.1 +/- 4.5 (mean +/- SD) years with recurrent paroxysmal supraventricular tachycardia underwent an electrophysiological study. Eleven patients had an overt and seven had a concealed accessory connection; six patients had no accessory connection. An orthodromic reciprocating tachycardia was inducible in 17 of 18 patients with an accessory connection, and an atrioventricular nodal reentrant tachycardia was inducible in four of six patients without accessory connection. After administration of propafenone, the sinus cycle length decreased. Intra-arterial, intranodal, and His-ventricle intervals and QRS duration increased. The atrial and ventricular effective refractory periods and anterograde and retrograde effective refractory periods of the atrioventricular node increased. The cycle length at which nodal second-degree block occurred increased. Of 18 patients with accessory connection, propafenone prolonged retrograde conduction in all, blocked anterograde conduction in five, and prolonged it in six. The drug terminated the orthodromic reciprocating tachycardia in all 17 patients and the atrioventricular nodal reentrant tachycardia in three of four patients. In three of four patients with atrioventricular nodal reentrant tachycardia and in 15 of 17 patients with orthodromic reciprocating tachycardia, the tachycardia was no longer inducible or nonsustained after propafenone. A follow-up of 26 +/- 10 months revealed that the drug when orally administered to all patients prevented recurrences of tachycardia in 15 of 18 patients with and in four of six patients without accessory connection. The results of short-term drug testing with propafenone predict the response to long-term oral therapy with this drug.
No takes yet. Share an insight, caveat, or question.
Musto et al. (1988) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: